<DOC>
	<DOCNO>NCT01773772</DOCNO>
	<brief_summary>The purpose study learn gonadotropin-releasing hormone ( GnRH ) luteinizing hormone ( LH ) pulse control puberty . In study , investigator aim discover whether give 2 small dos progesterone early pubertal girl prevent nighttime increase GnRH LH pulse . From information gather study , investigator may able learn menstrual cycle normally establish girl puberty . Ultimately , normal process understood , investigator may able good understand abnormality puberty .</brief_summary>
	<brief_title>Progesterone Suppression Nocturnal LH Increases Pubertal Girls</brief_title>
	<detailed_description>We recruit early pubertal , premenarcheal adolescent girl , since stage associate prominent diurnal variation LH pulsatility ( 13 ) . Weight normal height ( i.e. , BMI ≤ 85th ≥ 5th percentile age accord CDC ) , plasma testosterone &lt; 40 ng/dl . We recruit normal adolescent girl , girl idiopathic short stature ( &gt; 2 SD mean height age identifiable cause ) , UVa Pediatric Clinics , local pediatric clinic , Teen Health Center , UVa Endocrine Clinics . Subjects late Tanner 1 ( define estradiol level &gt; 20 pg/mL ) , Tanner 2 , Tanner 3 . All potential subject undergo screen history physical prior enrollment . These 60-90 min outpatient visit CRU alternate UVA clinical unit establish general health developmental normality . Evaluation include complete personal family medical history physical examination ( include height , weight , pubertal stage determination use Tanner scale ) . The goal procedure study explain potential subject parent , question entertain . The volunteer parent sign assent consent form , respectively . Blood ( 20 ml ) drawn ( approx . 0800-0900 h ) follow test : LH , FSH , P , E2 , total testosterone , SHBG , DHEA-S , 17-OHP , beta-hCG , TSH , CBC , chemistry liver panel , prolactin , insulin , Insulin-like Growth Factor 1 ( IGF-1 ) , cytokine adipokines ( include adiponectin , leptin , resistin , PAI-1 , IL-1b , IL-6 , IL-8 , TNFa , MCP-1 , HGF NGF ) . Subjects need fast minimum 8 hour prior screen blood draw . Bone age ( plain x-ray left hand wrist ) also perform marker biological age , since pubertal stage generally correlate well bone age chronological age . If screen lab show hemoglobin &lt; 11.0g/dL African American subject hemoglobin &lt; 11.5 g/dL non-African American subject , iron therapy dose 1-2 mg/kg encourage 60 day . Subjects weigh ≤ 36 kg give 300-325 mg oral ferrous gluconate daily ( contain 36 mg elemental iron ) ; subject weigh &gt; 36 kg give 300-325 mg oral ferrous gluconate twice daily . Hemoglobin rechecked CRU clinical unit ; acceptable ( hemoglobin ≥ 11 g/dL African American subject hemoglobin ≥ 11.5 g/dL non-African American subject ) , inpatient admission schedule . If screening lab normal , iron supplementation dose 1-2 mg/kg 30 day give help prevent anemia develop study . Subjects weigh ≤ 36 kg give 300-325 mg oral ferrous gluconate daily ( contain 36 mg elemental iron ) ; subject weigh &gt; 36 kg give 300-325 mg oral ferrous gluconate twice daily . If safety labs abnormal screening ( e.g. , abnormal liver test , abnormal TSH ) , subject ask return repeat ( confirmatory ) labs exclude lab error . Repeat test generally occur within one month original screening lab draw . If exclusionary lab value confirm repeat testing , subject exclude participation . 1-3 day overnight admission : An outpatient blood sample obtain 1-3 overnight admission . Plasma P check exclude unlikely luteal phase , overnight admission cancel P exceed 1.5 ng/ml . Hemoglobin obtain obtain within 30 day overnight admission ( subsequent overnight admission cancel hemoglobin &lt; 11 g/dl African American subject &lt; 11.5 g/dL non-African American subject ) . Urine beta-HCG assess exclude pregnancy . If three month elapse overnight admission subject 's recent safety lab , additional safety lab ( chemistry liver panel ) obtain time . Inpatient Admission : Subjects admit CRU , alternate UVA hospital unit , off-site hotel 1400 h. In general , parent welcome stay child off-site hotel wish . If overnight portion study do off-site hotel , subject may stay without parent legal guardian , long two CRU staff present . Whether parent need remain overnight admission discuss visit schedule . An i.v . line place forearm vein ( may facilitate EMLA cream ) , side dominant hand possible . Subjects take 25-50 mg oral micronized P placebo 1600 h 2000 h. P dosing base weight , 25 mg administer girl &lt; 42 kg 50 mg give ≥ 42 kg ; P administration , aim produce mean P concentration approximately 2-3 ng/ml . Frequent blood sample begin 1900 h continue 14 h follow : LH every 10 min ( 1 ml ) ; FSH every 10 min ( additional blood require ) ; P , E2 , T , DHEA cortisol every 30 min ( 1 ml ) . An additional 0.3 cc sample drawn 0700 test fast glucose . Fasting insulin , SHBG , estrone , androstenedione , DHEA-S perform pooled sample 05:00-07:00 . Lights extinguish 2200 h facilitate sleep , carefully record trained observer . During blood sampling , activity ( e.g . awake , sleep ) record nurse every 10 minute . Additionally , period sleep estimate use wrist actigraphy ( Motionlogger Basic-L ; Ambulatory Monitoring , Inc. ) The Motionlogger Basic-L watch-like device ( include accelerometer ) wear non-dominant wrist research participant overnight admission . There overnight fast 22:00 07:00 . Subjects awaken 0700 h. Sampling cease 0900 h. During admission , ~150 ml blood drawn ( include 0.25 ml discard sample ) . The total amount blood drawn study , include screening , outpatient P sampling , inpatient admission ~170 ml . One parent allow stay overnight subject admission . After last sample take , volunteer discharge oral iron supplementation take 30 d. Follow-up : We advance every effort follow subject ( via outpatient CRU clinic visit ) 6- 12-month interval 3 assess progression puberty , onset frequency menses , development sign hyperandrogenism ( e.g. , hirsutism ) . We obtain blood LH , FSH , E2 , P , T follow-up visit . These follow-up visit encourage , mandatory .</detailed_description>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Female volunteer early midpuberty ( i.e . late Tanner 1 [ estradiol level &gt; 20 pg/ml ] , Tanner 2 , Tanner 3 ) Premenarcheal BMIforage &gt; 85th percentile &lt; 5th percentile Pregnancy Inability comprehend do study do Hyperandrogenism ( e.g. , hirsutism , elevate free testosterone level ) History allergy progesterone ( extremely rare ) Hemoglobin le 12 g/dl hematocrit le 36 % Persistently abnormal sodium , potassium , bicarbonate ( i.e . confirm repeat ) Persistently elevate creatinine , hepatic transaminase , alkaline phosphatase ( i.e. , confirmed repeat ) Total bilirubin &gt; 1.5 time upper limit normal ( i.e . confirm repeat ) Significant history cardiac pulmonary dysfunction ( e.g. , know suspect congestive heart failure ; asthma require intermittent systemic corticosteroid ; etc . ) Untreated hypo hyperthyroidism , reflect persistently abnormal thyroidstimulating hormone ( TSH ) value Premature adrenarche ( i.e. , occur age 8 ) Basal ( follicular ) 17hydroxyprogesterone &gt; 200 ng/ml ( confirmed repeat ) Dehydroepiandrosteronesulfate ( DHEAS ) &gt; ageappropriate upper limit normal ( confirmed repeat ) Hyperprolactinemia ( confirm repeat ) Weight le 25 kg</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>